Clinical trials in CIDP and chronic autoimmune demyelinating polyneuropathies

Journal of the Peripheral Nervous System

Volumn 17, Issue SUPPL. 2, 2012, Pages 34-39

  Dalakas, Marinos C ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

alemtuzumab; anti MAG neuropathy; chonic inflammatory demyelinating polyneuropathy; IVIg; multifocal motor neuropathy

Indexed keywords

AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; IMMUNOGLOBULIN; METHOTREXATE; MYCOPHENOLIC ACID;

ANTIMYELIN ASSOCIATED GLYCOPROTEIN DEMYELINATING NEUROPATHY; B LYMPHOCYTE; CHRONIC AUTOIMMUNE DEMYELINATING POLYNEUROPATHY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CONTROLLED CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; MOTOR NEUROPATHY; NEUROPATHY; PARAPROTEINEMIA; PLASMAPHERESIS; POLYNEUROPATHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCORING SYSTEM; T LYMPHOCYTE;

HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; POLYRADICULONEUROPATHY; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84860625167     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2012.00393.x     Document Type: Review

References (49)

1. Benedetti L, Briani C, Franciotta D, Fazio R, Paolasso I, Comi C, Luigetti M, Sabatelli M, Giannini F, Mancardi GL, Schenone A, Nobile-Orazio E, Cocito D, (2011a). Rituximab in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a report of 13 cases and review of the literature. J Neurol Neurosurg Psychiatry 82: 306-308.
2. Benedetti L, Zardini E, Briani C, Beronio A, Gastaldi S, Jarius S, Mancardi GL, Schenone A, Franciotta D, (2011b). B-cell-activating factor in rituximab-treated patients with anti-MAG polyneuropathy. J Neurol Neurosurg Psychiatry 82: 1291-1294.
3. Briani C, Zara G, Zambello R, Trentin L, Rana M, Zaja F, (2004). Rituximab-responsive CIDP. Eur J Neurol 11: 788.
4. Bril V, Banach M, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung HP, Hughes RA, Katzberg H, Latov N, Merkies IS, Van Doorn PA,;, ICE Study Group, (2010). Electrophysiologic correlations with clinical outcomes in CIDP. Muscle Nerve 42: 492-497.
5. Chan YC, Allen DC, Fialho D, Mills KR, Hughes RA, (2006). Predicting response to treatment in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 77: 114-116. (Pubitemid 43022709)
6. Dalakas MC, (2008a). Autoimmune peripheral neuropathies. In: Clinical Immunology: Principles and Practice, 3rd Edn., Rich RR, Fleisher TA, Shearer WT, (Eds). Mosby Elsevier, Philadelphia, pp 977-994.
7. Dalakas MC, (2008b). B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 4: 557-567.
8. Dalakas MC, (2008c). Invited article: inhibition of B cell functions: implications for neurology. Neurology 70: 2252-2260.
9. Dalakas MC, (2011a). Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7: 507-517.
10. Dalakas MC, (2011b). Potential biomarkers for monitoring therapeutic responses to IVIg and other therapies in CIDP. J Peripher Nerv Syst 16: 63-67.
11. Dalakas MC, Engel WK, (1980). Immunoglobulin and complement deposits in nerves of patients with chronic relapsing polyneuropathy. Arch Neurol 37: 637-640. (Pubitemid 10018490)
12. Dalakas MC, Engel WK, (1981). Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 9 (Suppl): 134-145. (Pubitemid 11120646)
13. Dalakas MC, Quarles RH, (1996). Autoimmune ataxic neuropathies (sensory ganglionopathies): are glycolipids the responsible autoantigens? Ann Neurol 39: 419-422. (Pubitemid 26117995)
14. Dalakas MC, Quarles RH, Farrer RG, Dambrosia J, Soueidan S, Stein DP, Cupler E, Sekul EA, Otero C, (1996). A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40: 792-795. (Pubitemid 26415192)
15. Dalakas MC, Rakocevic G, Salajegheh M, Dambrosia JM, Hahn AF, Raju R, McElroy B, (2009). Placebo-controlled trial of rituximab in IgM anti-myelin associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 65: 286-293.
16. Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, Mokri B, Swift T, Low PA, Windebank AJ, (1982). Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 11: 136-141. (Pubitemid 12162978)
17. Dyck PJ, Daube J, O'Brien P, Pineda A, Low PA, Windebank AJ, Swanson C, (1986). Plasma exchange in chronic inflammatory demyelinating polyradiculoneuropathy. N Engl J Med 314: 461-465. (Pubitemid 16161945)
18. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, Windebank AJ, Karnes JL, O'Brien PC, (1994). A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36: 838-845. (Pubitemid 24370922)
19. Fitzpatrick AM, Mann CA, Barry S, Brennan K, Overell JR, Willison HJ, (2011). An open label clinical trial of complement inhibition in multifocal motor neuropathy. J Peripher Nerv Syst 16: 84-91.
20. Gorson KC, van Schaik IN, Merkies IS, Lewis RA, Barohn RJ, Koski CL, Cornblath DR, Hughes RA, Hahn AF, Baumgarten M, Goldstein J, Katz J, Graves M, Parry G, van Doorn PA, (2010). Chronic inflammatory demyelinating polyneuropathy disease activity status: recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 15: 326-333.
21. Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, Shumak K, Vandervoort MK, Feasby TE, (1996). Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A doubleblind, sham-controlled, cross-over study. Brain 119: 1055-1066. (Pubitemid 26300708)
22. Hartung HP, Lehmann HC, Willison HG, (2011). Peripheral neuropathies: establishing common clinical research standards for CIDP. Nat Rev Neurol 7: 250-251.
23. Hughes R, Bensa S, Willison H, Van den Bergh P, Comi G, Illa I, Nobile-Orazio E, van Doorn P, Dalakas M, Bojar M, Swan A,; Inflammatory Neuropathy Cause and Treatment (INCAT) Group (2001). Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50: 195-201. (Pubitemid 32738144)
24. Hughes R, Swan A, van Doorn P, (2004). Cytotoxic drugs and interferons for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 4: CD003280.
25. Hughes RA, Allen D, Makowska A, Gregson NA, (2006). Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 11: 30-46. (Pubitemid 43344973)
26. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA,;, ICE Study Group, (2008). Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144.
27. Hughes RA, Gorson KC, Cros D, Griffin J, Pollard J, Vallat JM, Maurer SL, Riester K, Davar G, Dawson K, Sandrock A,; Avonex CIDP Study Group (2010). Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 74: 651-657.
28. Iijima M, Tomita M, Morozumi S, Kawagashira Y, Nakamura T, Koike H, Katsuno M, Hattori N, Tanaka F, Yamamoto M, Sobue G, (2009). Single nucleotide polymorphism of TAG-1 influences IVIg responsiveness of Japanese patients with CIDP. Neurology 73: 1348-1352.
29. Ilyas AA, Quarles RH, Dalakas MC, Brady RO, (1985). Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins. Proc Natl Acad Sci U S A 82: 6697-6700. (Pubitemid 16228887)
30. Joint Task Force of the EFNS and the PNS (2010) European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. First revision. J Peripher Nerv Syst 15: 1-9.
31. Kazmi MA, Mahdi-Rogers M, Sanvito L, (2008). Chronic inflammatory demyelinating polyradiculoneuropathy: a role for haematopoietic stem cell transplantation? Autoimmunity 41: 611-615.
32. Koller H, Kieseier BC, Jander S, Hartung HP, (2005). Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 352: 1343-1356.
33. Kosmidis ML, Dalakas MC, (2010). Practical considerations on the use of rituximab in autoimmune neurological disorders. Ther Adv Neurol Disord 3: 93-105.
34. Latov N, Hays A, Sherman WH, (1988). Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 3: 301-332.
35. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA,; IGIV-C CIDP Efficacy (ICE) Study Group (2010). Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 67: 802-807.
36. Laughlin RS, Dyck PJ, Melton LJ, 3rd, Leibson C, Ransom J, (2009). Incidence and prevalence of CIDP and the association of diabetes mellitus. Neurology 73: 39-45.
37. Lee DH, Linker RA, Paulus W, Schneider-Gold C, Chan A, Gold R, (2008). Subcutaneous immunoglobulin infusion: a new therapeuticoption in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 37: 406-409. (Pubitemid 351304803)
38. Léger JM, Viala K, Nicolas G, Créange A, Vallat JM, Pouget J, Clavelou P, Marin B,; for the RIMAG Trial Group (France and Switzerland) (2011). A randomized placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy (RIMAG Study). J Peripher Nerv Syst 16: S73.
39. Mahdi-Rodgers M, Swan AV, van Doorn PA, Hughes RA, (2010). Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for CIDP. Cochrane Database Syst Rev 11: CD003280.
40. Marsh EA, Hirst CL, Llewelyn JG, Cossburn MD, Reilly MM, Krishnan A, Doran M, Ryan AM, Coles AJ, Jones JL, Robertson NP, (2010). Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 257: 913-919.
41. Merkies IS, Bril V, Dalakas MC, Deng C, Donofrio P, Hanna K, Hartung HP, Hughes RA, Latov N, van Doorn PA,; ICE Study Group (2009). Health-related quality-of-life improvements in CIDP with immune globulin IV 10%: the ICE Study. Neurology 72: 1337-1344.
42. Münch C, Anagnostou P, Meyer R, Haas J, (2007). Rituximab in chronic inflammatory demyelinating polyneuropathy associated with diabetes mellitus J Neurol Sci 256: 100-102. (Pubitemid 46560632)
43. Rajabally YA, Simpson BS, Beri S, Bankart J, Gosalakkal JA, (2009). Epidemiologic variability of chronic inflammatory demyelinating polyneuropathy with different diagnostic criteria: study of a UK population. Muscle Nerve 39: 432-438.
44. RMC Trial Group (2009). Randomised controlled trial of methotrexate for chronic inflammatory demyelinating polyradiculoneuropathy (RMC trial): a pilot, multicentre study. Lancet Neurol 8: 158-164.
45. Tackenberg B, Jelcic I, Baerenwaldt A, Oertel WH, Sommer N, Nimmerjahn F, Lünemann JD, (2009). Impaired inhibitory Fcgamma receptor IIB expression on B cells in chronic inflammatory demyelinating polyneuropathy. Proc Natl Acad Sci U S A 106: 4788-4792.
46. Vallat JM, Sommer C, Magy L, (2010). Chronic inflammatory demyelinating polyradiculoneuropathy: diagnostic and therapeutic challenges for a treatable condition. Lancet Neurol 9: 402-412.
47. Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, Van den Berg LH, (2005). Multifocal motor neuropathy. Lancet Neurol 4: 309-319. (Pubitemid 40545042)
48. Vermeulen M, Van Oers MH, (2002). Successful autologous stem cell transplantation in a patient with chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 72: 127-128. (Pubitemid 34073115)
49. Wolf C, Menge T, Stenner MP, Meyer zu Hörste G, Saleh A, Hartung HP, Wiendl H, Kieseier BC, (2010). Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy. Arch Neurol 67: 881-883.